



PRESS RELEASE, 23 October 2002

Perbio Science AB

Interim report

January-September 2002

Continued growth despite weaker US dollar

- Net sales up 19 % to SEK 1,663 (1,396) million
- Operating profit before amortisation of goodwill up 18 % to SEK 306 (260) million
- Profit after financial items up 16 % to SEK 276 (237) million after exchange losses of SEK 4 million (gains of SEK 15 million)
- Net profit up 17 % to SEK 168 (143) million

“The lower growth in profits is because we during the third quarter experienced exceptionally high sales of amidites with low margins, high relative sales of Cell Culture products, weaker dollar and lower serum sales due to lower serum raw material supply”, says **CEO Mats Fischier**.

FURTHER INFORMATION

CEO Mats Fischier

tel +46 42 26 90 91 or +46 70 595 18 21

CFO Claes Wentzel

tel +46 42 26 90 92 or +46 70 862 01 22

More information on Perbio Science can also be found on our website at www.perbio.com